Table 4 Specific adverse events with an incidence ≥2% in one or more treatment group by system organ class
Omarigliptin N = 153 | Placebo N = 153 | |
|---|---|---|
General disorders and administration site conditions | ||
Chest discomfort | 3 (3.0) | 0 (0.0) |
Infections and infestations | ||
Influenza | 3 (2.0) | 0 (0.0) |
Nasopharyngitis | 4 (2.6) | 5 (3.3) |
Rhinitis | 3 (2.0) | 1 (0.7) |
Upper respiratory tract infection | 4 (2.6) | 9 (5.9) |
Urinary tract infection | 9 (5.9) | 3 (2.0) |
Investigations | ||
Blood creatine phosphokinase increased | 2 (1.3) | 3 (2.0) |
Blood glucose increased | 1 (0.7) | 3 (2.0) |
Lipase increased | 5 (3.3) | 1 (0.7) |
Metabolism and nutrition disorders | ||
Hyperglycemia | 3 (2.0) | 6 (3.9) |
Hypoglycemia | 18 (11.8) | 13 (8.5) |
Musculoskeletal and connective tissue disorders | ||
Arthralgia | 3 (2.0) | 3 (2.0) |
Back pain | 4 (2.6) | 3 (2.0) |
Nervous system disorders | ||
Headache | 0 (0.0) | 3 (2.0) |